Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2013-01-18 Capital/Financing Update
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
FWP
Capital/Financing Update Classification · 100% confidence The document is titled 'Issuer Free Writing Prospectus' and is filed pursuant to Rule 433, which is a SEC rule related to free writing prospectuses used in securities offerings. It contains detailed information about a convertible subordinated notes offering by Theravance, Inc., including terms such as interest rate, maturity, conversion rate, use of proceeds, underwriting details, and pricing. The document is a pricing term sheet supplementing a preliminary prospectus and is clearly related to a capital raising activity. It is not a financial report, earnings release, or management discussion, but rather a disclosure document for a financing transaction. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length is sufficient and contains substantive details about the offering, not just an announcement or a brief summary, supporting a high confidence score.
2013-01-18 English
FWP
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC by Theravance, Inc. dated January 16, 2013. It includes an investor presentation as Exhibit 99.1, which is described as a "Company Overview Presentation." The text contains forward-looking statements, expense guidance, and pipeline updates typical of investor presentations. There is no detailed financial statement or comprehensive financial analysis that would qualify it as an Annual Report (10-K) or Interim Report (IR). The document is not an earnings release, audit report, or regulatory filing of a different nature. The presence of a detailed presentation focused on company strategy, financial guidance, and market position aligns with the definition of an Investor Presentation (IP). The document length is substantial (15,000 characters), indicating it is the actual presentation, not just an announcement of its publication. Therefore, the most appropriate classification is Investor Presentation (IP).
2013-01-16 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes an investor presentation as an exhibit and discusses forward-looking statements and expense guidance, but it does not contain comprehensive financial statements or detailed financial analysis typical of an earnings release or interim report. The document is not an annual report, audit report, or any other detailed financial report. It is primarily an announcement of an event and includes an investor presentation. Therefore, the filing type corresponds to a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2013-01-16 English
FWP
Capital/Financing Update Classification · 100% confidence The document is a press release announcing Theravance, Inc.'s intention to offer $250 million in convertible subordinated notes due 2023. It details the terms of the offering, use of proceeds, and hedging transactions related to the convertible notes. The document is a free writing prospectus (FWP) filed pursuant to Rule 433, which is a type of offering document related to capital raising activities. There is no financial statement data or comprehensive financial analysis present, and the document is not an earnings release or annual/interim report. It is clearly an update on a financing activity, specifically a debt offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (8889 characters) supports that it is a substantive announcement rather than a brief notice or report publication announcement.
2013-01-16 English
S-3ASR
Capital/Financing Update Classification · 100% confidence The document is a Form S-3ASR registration statement filed with the SEC, which is a type of registration statement used for securities offerings. It includes a prospectus for convertible subordinated notes and common stock, detailing the terms of the offering, underwriting, risk factors, and other related information. This is a capital raising document related to financing activities, not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update filings.
2013-01-16 English
FORM 4 -
Director's Dealing
2013-01-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.